Akebia Therapeutics Inc

More Details of Akebia Therapeutics Inc Company

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Company Info

Company codeAKBA

Company nameAkebia Therapeutics Inc

IPO dateMar 20, 2014

Founded at2007

CEOMr. John P. Butler

Number of employees181

Security typeOrdinary Share

Fiscal year-endMar 20

Address245 First Street

CityCAMBRIDGE

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code02142

Phone16178712098

Websitehttps://akebia.com/

Company codeAKBA

IPO dateMar 20, 2014

Founded at2007

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

134.80K

--

Mr. Michael W. Rogers

Independent Director

96.03K

--

Ms. Cynthia Smith

Independent Director

95.23K

--

Dr. Steven C. Gilman, Ph.D.

Independent Director

87.13K

--

Dr. Myles Wolf, M.D.

Independent Director

67.68K

--

Mr. Nicholas (Nik) Grund

Senior Vice President, Chief Commercial Officer

45.48K

-89.72%

Ms. Leanne M. Zumwalt

Independent Director

43.70K

--

Mr. Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer

--

-100.00%

Dr. Steven K. Burke, M.D.

Senior Vice President - Research and Development, Chief Medical Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

134.80K

--

Mr. Michael W. Rogers

Independent Director

96.03K

--

Ms. Cynthia Smith

Independent Director

95.23K

--

Dr. Steven C. Gilman, Ph.D.

Independent Director

87.13K

--

Dr. Myles Wolf, M.D.

Independent Director

67.68K

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholder

Update time: Sat, May 17

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

BlackRock Institutional Trust Company, N.A.

5.32%

The Vanguard Group, Inc.

4.83%

State Street Global Advisors (US)

2.59%

Alerce Investment Management, L.P.

2.19%

Satter Muneer A

2.19%

Other

82.88%

Shareholder Statistics

Shareholder

Proportion

BlackRock Institutional Trust Company, N.A.

5.32%

The Vanguard Group, Inc.

4.83%

State Street Global Advisors (US)

2.59%

Alerce Investment Management, L.P.

2.19%

Satter Muneer A

2.19%

Other

82.88%

Type

Shareholder

Proportion

Investment Advisor/Hedge Fund

15.41%

Hedge Fund

9.31%

Investment Advisor

8.54%

Individual Investor

3.52%

Private Equity

3.03%

Research Firm

2.48%

Bank and Trust

0.14%

Insurance Company

0.03%

Pension Fund

0.02%

Other

57.54%

Institutional Shareholding

Update time: Sat, Feb 22

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

259

82.69M

31.59%

+8.81M

2024Q4

258

78.54M

36.08%

+7.41M

2024Q3

257

64.16M

30.51%

-2.18M

2024Q2

248

61.31M

29.27%

-7.52M

2024Q1

290

61.37M

29.36%

-12.30M

2023Q4

289

58.79M

31.24%

-20.79M

2023Q3

300

57.28M

30.45%

-25.18M

2023Q2

308

56.18M

30.22%

-26.52M

2023Q1

315

56.14M

30.23%

-26.40M

2022Q4

328

55.82M

30.36%

-25.38M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

13.84M

5.54%

-201.31K

-1.43%

Dec 31, 2024

The Vanguard Group, Inc.

10.88M

4.36%

+813.90K

+8.08%

Dec 31, 2024

State Street Global Advisors (US)

6.30M

2.52%

+2.87M

+83.78%

Dec 31, 2024

Alerce Investment Management, L.P.

5.75M

2.3%

--

Dec 31, 2024

Satter Muneer A

5.75M

2.3%

+5.75M

--

Dec 31, 2024

Geode Capital Management, L.L.C.

4.80M

1.92%

+40.63K

+0.85%

Dec 31, 2024

Renaissance Technologies LLC

3.82M

1.53%

+105.73K

+2.84%

Dec 31, 2024

Citadel Advisors LLC

1.38M

0.55%

+1.38M

--

Dec 31, 2024

Related ETFs

Update time: Tue, May 6

Name

Proportion

Invesco NASDAQ Future Gen 200 ETF

0.49%

Federated Hermes MDT Small Cap Core ETF

0.16%

iShares Micro-Cap ETF

0.09%

SPDR S&P Biotech ETF

0.08%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.08%

Direxion Daily S&P Biotech Bull 3X Shares

0.05%

Fidelity Enhanced Small Cap ETF

0.05%

iShares Russell 2000 Value ETF

0.03%

iShares Russell 2000 ETF

0.02%

Global X Russell 2000 ETF

0.02%

Invesco NASDAQ Future Gen 200 ETF

Proportion0.49%

Federated Hermes MDT Small Cap Core ETF

Proportion0.16%

iShares Micro-Cap ETF

Proportion0.09%

SPDR S&P Biotech ETF

Proportion0.08%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proportion0.08%

Direxion Daily S&P Biotech Bull 3X Shares

Proportion0.05%

Fidelity Enhanced Small Cap ETF

Proportion0.05%

iShares Russell 2000 Value ETF

Proportion0.03%

iShares Russell 2000 ETF

Proportion0.02%

Global X Russell 2000 ETF

Proportion0.02%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

2.800USD